Top

Published in:

Open Access 01-12-2015 | Review

Breast cancer brain metastases: the last frontier

Authors: José Pablo Leone, Bernardo Amadeo Leone

Published in: Experimental Hematology & Oncology | Issue 1/2015

Abstract

Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10–16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival. In addition, brain metastases are a major cause of morbidity, associated with progressive neurologic deficits that result in a reduced quality of life. Tumor subtypes play a key role in prognosis and treatment selection. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial and careful patient selection by using available prognostic tools is extremely important. This review will focus on current treatment options, novel therapies, future approaches and ongoing clinical trials for patients with breast cancer brain metastases.

Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(17):3608–17. doi:10.1200/JCO.2004.01.175.CrossRef

Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother. 2010;11(7):1089–100. doi:10.1517/14656561003702412.CrossRefPubMed

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167(4):913–20. doi:10.1016/S0002-9440(10)61180-7.PubMedCentralCrossRefPubMed

Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84. doi:10.1038/nrc2622.CrossRefPubMed

Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med. 2015;4(7):989–94. doi:10.1002/cam4.439.PubMedCentralCrossRefPubMed

Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(36):5658–63. doi:10.1200/JCO.2006.07.0250.CrossRef

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107(4):696–704. doi:10.1002/cncr.22041.CrossRefPubMed

Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2006;17(6):935–44. doi:10.1093/annonc/mdl064.CrossRef

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res BCR. 2008;10(1):R20. doi:10.1186/bcr1870.CrossRefPubMed

10.

Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23(5):623–8. doi:10.1016/j.breast.2014.06.009.CrossRefPubMed

11.

Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neuro-Oncol. 2013;112(3):467–72. doi:10.1007/s11060-013-1083-9.CrossRef

12.

Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat. 2008;111(3):523–30. doi:10.1007/s10549-007-9806-2.CrossRefPubMed

13.

Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, et al. Treatment and prognosis of brain metastases from breast cancer. J Neuro-Oncol. 2008;86(2):231–8. doi:10.1007/s11060-007-9469-1.CrossRef

14.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111–7. doi:10.1016/j.ijrobp.2011.02.027.PubMedCentralCrossRefPubMed

15.

Klos KJ, O’Neill BP. Brain metastases. Neurol. 2004;10(1):31–46. doi:10.1097/01.nrl.0000106922.83090.71.CrossRef

16.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2008;19(7):1242–8. doi:10.1093/annonc/mdn036.CrossRef

17.

Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45. doi:10.1002/cncr.23930.PubMedCentralCrossRefPubMed

18.

Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, Gonzalez-Jimenez S, et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico. 2014;16(5):436–46. doi:10.1007/s12094-013-1110-5.

19.

Niwinska A, Pogoda K, Murawska M, Niwinski P. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2011;37(7):635–42. doi:10.1016/j.ejso.2011.05.002.

20.

Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2010;21(5):942–8. doi:10.1093/annonc/mdp407.CrossRef

21.

Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014;147(1):103–12. doi:10.1007/s10549-014-3090-8.CrossRefPubMed

22.

Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117(8):1602–11. doi:10.1002/cncr.25746.PubMedCentralCrossRefPubMed

23.

Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neuro-oncol. 2008;88(3):359–65. doi:10.1007/s11060-008-9578-5.CrossRef

24.

Lentzsch S, Reichardt P, Weber F, Budach V, Dorken B. Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer. 1999;35(4):580–5.CrossRefPubMed

25.

Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PloS One. 2014;9(2):e89389. doi:10.1371/journal.pone.0089389.PubMedCentralCrossRefPubMed

26.

Nieder C, Marienhagen K, Astner ST, Molls M. Prognostic scores in brain metastases from breast cancer. BMC Cancer. 2009;9:105. doi:10.1186/1471-2407-9-105.PubMedCentralCrossRefPubMed

27.

Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4. doi:10.1016/j.ijrobp.2007.06.074.CrossRefPubMed

28.

Sperduto CM, Watanabe Y, Mullan J, Hood T, Dyste G, Watts C, et al. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg. 2008;109(Suppl):87–9. doi:10.3171/JNS/2008/109/12/S14.PubMed

29.

Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(20):2239–45. doi:10.1200/JCO.2014.58.8517.CrossRef

30.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500. doi:10.1056/NEJM199002223220802.CrossRefPubMed

31.

Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583–90. doi:10.1002/ana.410330605.CrossRefPubMed

32.

Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–6.CrossRefPubMed

33.

Sause WT, Crowley JJ, Morantz R, Rotman M, Mowry PA, Bouzaglou A, et al. Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery +RT versus RT alone. Am J Clin Oncol. 1990;13(5):427–32.CrossRefPubMed

34.

Ampil FL, Nanda A, Willis BK, Nandy I, Meehan R. Metastatic disease in the cerebellum. The LSU experience in 1981–1993. Am J Clin Oncol. 1996;19(5):509–11.CrossRefPubMed

35.

Rades D, Kieckebusch S, Haatanen T, Lohynska R, Dunst J, Schild SE. Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. Int J Radiat Oncol Biol Phys. 2008;70(5):1319–24. doi:10.1016/j.ijrobp.2007.08.009.CrossRefPubMed

36.

Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427–34.CrossRefPubMed

37.

Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53(3):519–26.CrossRefPubMed

38.

Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-oncol. 2010;96(1):45–68. doi:10.1007/s11060-009-0073-4.CrossRef

39.

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72. doi:10.1016/S0140-6736(04)16250-8.CrossRefPubMed

40.

Roberge D, Petrecca K, El Refae M, Souhami L. Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases. J Neuro-oncol. 2009;95(1):95–9. doi:10.1007/s11060-009-9899-z.CrossRef

41.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Jama. 2006;295(21):2483–91. doi:10.1001/jama.295.21.2483.CrossRefPubMed

42.

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44. doi:10.1016/S1470-2045(09)70263-3.CrossRefPubMed

43.

Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2012;118(9):2486–93. doi:10.1002/cncr.26515.CrossRefPubMed

44.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95. doi:10.1016/S1470-2045(14)70061-0.CrossRefPubMed

45.

Chang WS, Kim HY, Chang JW, Park YG, Chang JH. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? J Neurosurg. 2010;113(Suppl):73–8.PubMed

46.

Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Barfod BE, et al. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1–4 vs ≥5 tumors: clinical article. J Neurosurg. 2013;118(6):1258–68. doi:10.3171/2013.3.JNS121900.CrossRefPubMed

47.

Ojerholm E, Lee JY, Kolker J, Lustig R, Dorsey JF, Alonso-Basanta M. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery. Cancer Med. 2014;3(3):565–71. doi:10.1002/cam4.206.PubMedCentralCrossRefPubMed

48.

Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol. 2005;4(5):289–98. doi:10.1016/S1474-4422(05)70072-7.CrossRefPubMed

49.

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Jama. 1998;280(17):1485–9.CrossRefPubMed

50.

Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(2):134–41. doi:10.1200/JCO.2010.30.1655.CrossRef

51.

Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(1):65–72. doi:10.1200/JCO.2011.41.0639.CrossRef

52.

Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(10):1260–6. doi:10.1200/JCO.2006.09.2536.CrossRef

53.

Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–95. doi:10.1016/j.ijrobp.2007.03.048.CrossRefPubMed

54.

Brown PD, Asher AL, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1–3 brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(suppl; abstr LBA4).

55.

Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, et al. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology. 2012;83(3):141–50. doi:10.1159/000338782.CrossRefPubMed

56.

Colomer R, Cosos D, Del Campo JM, Boada M, Rubio D, Salvador L. Brain metastases from breast cancer may respond to endocrine therapy. Breast Cancer Res Treat. 1988;12(1):83–6.CrossRefPubMed

57.

Pors H, von Eyben FE, Sorensen OS, Larsen M. Longterm remission of multiple brain metastases with tamoxifen. J Neuro-oncol. 1991;10(2):173–7.CrossRef

58.

Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neuro-oncol. 1995;24(3):299–301.CrossRef

59.

Madhup R, Kirti S, Bhatt ML, Srivastava PK, Srivastava M, Kumar S. Letrozole for brain and scalp metastases from breast cancer–a case report. Breast. 2006;15(3):440–2. doi:10.1016/j.breast.2005.07.006.CrossRefPubMed

60.

Goyal S, Puri T, Julka PK, Rath GK. Excellent response to letrozole in brain metastases from breast cancer. Acta Neurochir. 2008;150(6):613–4 (discussion 4-5). doi:10.1007/s00701-008-1576-z.

61.

Ito K, Ito T, Okada T, Watanabe T, Gomi K, Kanai T, et al. A case of brain metastases from breast cancer that responded to anastrozole monotherapy. Breast J. 2009;15(4):435–7. doi:10.1111/j.1524-4741.2009.00756.x.CrossRefPubMed

62.

Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63(4):641–5.PubMedCentralCrossRefPubMed

63.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34. doi:10.1056/NEJMoa1413513.CrossRefPubMed

64.

Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(11):2349–51.

65.

Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncol. 2008;13(7):739–50. doi:10.1634/theoncologist.2008-0052.CrossRef

66.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–92. doi:10.1038/clpt.2010.12.CrossRefPubMed

67.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med Off Publ Soc Nucl Med. 2013;54(11):1869–75. doi:10.2967/jnumed.112.118612.

68.

Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-oncol. 2007;85(3):311–7. doi:10.1007/s11060-007-9420-5.CrossRef

69.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(14):4834–43. doi:10.1158/1078-0432.CCR-10-2962.CrossRef

70.

Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075–82. doi:10.1038/bjc.2012.346.PubMedCentralCrossRefPubMed

71.

Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894–900. doi:10.1038/sj.bjc.6604941.PubMedCentralCrossRefPubMed

72.

Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):1993–9. doi:10.1200/JCO.2007.12.3588.CrossRef

73.

Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(4):1452–9. doi:10.1158/1078-0432.CCR-08-1080.CrossRef

74.

Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases–the UK experience. Br J Cancer. 2010;102(6):995–1002. doi:10.1038/sj.bjc.6605586.PubMedCentralCrossRefPubMed

75.

Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2011;22(3):625–30. doi:10.1093/annonc/mdq434.CrossRef

76.

Iwata H, Narabayashi M, Ito Y, Saji S, Fujiwara Y, Usami S, et al. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol. 2013;18(4):621–8. doi:10.1007/s10147-012-0444-2.CrossRefPubMed

77.

Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer. 2012;12:322. doi:10.1186/1471-2407-12-322.PubMedCentralCrossRefPubMed

78.

Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-1.CrossRefPubMed

79.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–43. doi:10.1007/s10549-007-9885-0.CrossRefPubMed

80.

Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(14):1564–73. doi:10.1200/JCO.2014.57.1794.CrossRef

81.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. doi:10.1056/NEJMoa1209124.CrossRefPubMed

82.

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2015;26(1):113–9. doi:10.1093/annonc/mdu486.CrossRef

83.

Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2014;25(6):1116–21. doi:10.1093/annonc/mdu133.CrossRef

84.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(19):2100–8. doi:10.1200/JCO.2013.54.0955.CrossRef

85.

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(19):2078–99. doi:10.1200/JCO.2013.54.0948.CrossRef

86.

Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58(4):832–9.CrossRefPubMed

87.

Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69(4):972–80.CrossRefPubMed

88.

Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85(7):1599–605.CrossRefPubMed

89.

Lorusso V, Galetta D, Giotta F, Rinaldi A, Romito S, Brunetti C, et al. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell’Italia Meridionale). Anticancer Res. 2006;26(3B):2259–63.PubMed

90.

Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada—Clinical Trials Group (NCIC-CTG). Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2006;17(6):952–6. doi:10.1093/annonc/mdl056.CrossRef

91.

Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neuro-oncol. 2005;71(1):61–5. doi:10.1007/s11060-004-9176-0.CrossRef

92.

Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–54. doi:10.1002/cncr.22127.CrossRefPubMed

93.

Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neuro-oncol. 2007;85(2):223–7. doi:10.1007/s11060-007-9409-0.CrossRef

94.

Lin NU, Gelman RS, Younger WJ, Sohl J, Freedman RA, Sorensen AG, et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(suppl; abstr 513).

95.

Lu YS, Chen WW, Lin CH, Tseng LM, Yeh DC, Wu PF, et al. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(suppl; abstr 1079).

96.

Leone JP, Bhargava R, Theisen BK, Hamilton RL, Lee AV, Brufsky AM. Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget. 2015;6(30):30327–33. doi:10.18632/oncotarget.4639.PubMed

97.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res BCR. 2011;13(6):R125. doi:10.1186/bcr3071.CrossRefPubMed

Title: Breast cancer brain metastases: the last frontier
Authors: José Pablo Leone
Bernardo Amadeo Leone
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Experimental Hematology & Oncology / Issue 1/2015
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/s40164-015-0028-8

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Distinct genetic alterations in small cell carcinoma from different anatomic sites

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors